Ed Amer, a partner in Goodwin's Private Equity group, represents private equity and venture capital firms, operating companies and investors in a broad range of transactions, including leveraged buyouts, carve-outs, exits, strategic collaborations, growth equity financings and general corporate representation, with a particular focus on the life science and healthcare industries. Prior to pursuing a career in law, Mr. Amer worked as a lighting technician in the motion picture industry.





Mr. Amer’s recent representations include:

  • Blackstone Life Sciences in its $400 million investment to accelerate the development and commercialization of nadofaragene firadenovec, an investigational gene therapy, with Ferring Pharmaceuticals.
  • Arranta Bio, a CDMO focused on providing development and commercialization services for therapeutic companies targeting the human microbiome, in its initial financing, strategic partnership with Thermo Fisher Scientific, and acquisition of Captozyme.
  • Shields Health Solutions, a specialty pharmacy integrator and care provider for hospitals, in connection with equity investments by Welsh, Carson, Anderson & Stowe and Walgreens.
  • Ampersand Capital Partners in its acquisition of a majority stake in N2 Biomedical, a leading provider of coating and surface treatment services for a wide range of medical and dental applications.
  • Teva Pharmaceuticals in the sale of its Plan B One Stop product and related assets to Foundation Consumer Healthcare.
  • Anthos Therapeutics in its $250 million financing by Blackstone Life Sciences and in-license of MAA868 from Novartis.
  • Ultragenyx, a biopharmaceutical company focused on rare diseases, in its acquisition of an exclusive option to acquire GeneTx, a start-up biotechnology company focused on Angelman syndrome.
  • Abide Therapeutics, a drug development company focused on CNS indications, in its acquisition by Lundbeck.
  • Fresenius Medical Care in the formation and initial funding of InterWell Health, a partnership with select nephrology practices across the United States focused on supporting the renal patient population across the full continuum of care.
  • Avista Pharma Solutions, a contract provider of drug substance, drug product and analytical services, in its sale to Cambrex Corporation.
  • ZOLL Medical, in its acquisitions of Payor Logic, a provider of RCM software solutions for the healthcare industry, and Golden Hour Data Systems, a provider of patient charting and RCM services in the EMS market.
  • Agilux Laboratories, an Ampersand Capital Partners portfolio company, in its sale to Charles River Laboratories.
  • Confluent Medical in its acquisitions of Interface Catheter Solutions, a contract manufacturer of balloon catheter systems, and Corpus Medical, a contract developer and manufacturer of interventional medical devices.
  • MPI research, an early stage drug development clinical research organization, in its sale to Avista Capital Partners.
  • Florida Biologix in its merger with Brammer Biopharmaceuticals, forming Brammer Bio, a cell and gene therapy biologics contract development and manufacturing organization, and Brammer Bio in its acquisition of a biologics manufacturing facility from Biogen.
  • Ampersand Capital Partners and 1315 Capital in their acquisition of Genoptix, an oncology diagnostics company, from Novartis, and in the subsequent sale of Genoptix to NeoGenomics Laboratories.
  • Primus Capital Partners in its investment in EnableComp, a healthcare technology company providing workers compensation reimbursement services.
  • Haven Healthcare, the health care delivery start-up founded by Amazon, Berkshire Hathaway and J.P. Morgan and led by Atul Gawande, in general corporate matters.
Professional Activities
Mr. Amer currently serves as Co-Chair of the M&A Committee of the Business Transaction Section of the Boston Bar Association.


In law school, Mr. Amer served on the Boston College Law Review and was a member of the Order of the Coif.

In The News









J.D., 2004
Boston College Law School

(magna cum laude)

B.A., 1992
Bowdoin College



Profile Image
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.


Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Search Other Lawyers
Recherche par Pratique